Interferon alpha and omega antibody antagonists

Patent metadata

Field	Value
Publication number	US-9902770-B2
Application number	US-201414208861-A
Country	US
Kind code	B2
Filing date	Mar 13, 2014
Priority date	Mar 15, 2013
Publication date	Feb 27, 2018
Grant date	Feb 27, 2018

Abstract

Broadly neutralizing interferon-α and interferon-ω antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of IFNα and IFNω.

First claim

We claim:

1. An isolated monoclonal antibody that binds human interferon omega (IFNω) at least at residues F27, L30 and R33 of SEQ ID NO: 1, wherein the antibody neutralizes an activity of IFNω, IFNαB2, IFNαC, IFNαF, IFNαG and IFNαJ1 and comprises a heavy chain variable region (VH) amino acid sequence of SEQ ID NO: 23 or SEQ ID NO:27 and a light chain variable region (VL) amino acid sequence of SEQ ID NO: 24 or SEQ ID NO: 28.

2. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

3. The antibody of claim 1 , wherein the antibody does not bind or neutralize human IFNα D.

4. The antibody of claim 1 , wherein the antibody neutralizes the activity of IFNα A, IFNα H2, IFNα K, IFNα WA and IFNα 4a.

5. The antibody of claim 4 , wherein the activity is inhibition of secreted embryonic alkaline phosphatase (SEAP) expression under the interferon inducible ISG54 promoter in HEK293 cells stably expressing signal transducer and activator of transcription 2 (STAT2), interferon regulatory factor 9 (IRF9) and SEAP.

6. The antibody of claim 5 , wherein the antibody neutralizes the activity of IFNω with an IC 50 value of between about 0.9×10 −9 M and about 1.85×10 −8 M.

7. The antibody of claim 6 , wherein the antibody binds IFNω with a dissociation constant (K D ) of between about 0.3×10 −9 M and about 4.5×10 −9 M, wherein the K D is measured using SPR technology with ProteOn (Bio-Rad Hercules, Calif.), with antibody loaded on an antibody coupled chip for 2 minutes at a flow rate of 30 μl/min, washing with running buffer for 2 minutes at a flow rate of 50 μl/ml, and associating recombinant IFN proteins at 5 different concentrations ranging from 100 nM to 1.23 nM with 1:3 dilution were for 3 minutes and dissociating for 10 minutes, both at the flow rate of 50 μl/ml.

8. The antibody of claim 4 , wherein the antibody inhibits an activity of viral-induced leukocyte interferon, wherein the activity of viral-induced leukocyte interferon is IP-10 release in whole blood induced by 100 U/ml of interferon.

9. The antibody of claim 8 , wherein the activity is inhibited by more than 50% in the presence of 50 μg/ml antibody.

10. The antibody of claim 4 , wherein the antibody does not bind or neutralize human interferon-β (IFNβ).

11. The antibody of claim 4 , wherein the antibody is human, humanized or human-adapted.

12. The antibody of claim 11 , wherein the antibody is of IgG1, IgG2, IgG3 or IgG4 isotype.

13. The antibody of claim 11 , wherein the antibody is bispecific.

14. The antibody of claim 13 , wherein the antibody binds BLyS, CD40L, IL-6, CD27, BDCA2 or the p40 subunit of IL-12 or IL-23.

15. A composition comprising the antibody of claim 14 and a pharmaceutically acceptable carrier.

Assignees

• Janssen Biotech Inc

Inventors

• Chi Ellen
• Connor Judith
• Huang Chichi
• Jordan Jarrat
• Lin Schmidt Xiefan
• Luo Jinquan
• Lu Lu
• Martinez Christian
• Obmolova Galina
• Swanson Ronald

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title